AGTC president and CEO Sue Washer said the company was moving ahead with two clinical studies further assessing its adeno-associated virus (AAV)-based XLRP gene therapy, named rAAV2tYF-GRK1-RPGRco: The Phase II/III VISTA trial (NCT04850118), which had yet to begin recruiting patients at deadline; and a Phase II expansion study called SKYLINE (NCT03316560 . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge